News
GLSI
13.99
-0.07%
-0.01
Weekly Report: what happened at GLSI last week (0422-0426)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 04/22 20:31
Weekly Report: what happened at GLSI last week (0415-0419)?
Weekly Report · 04/22 10:04
Greenwich Lifesciences Inc reports results for the quarter ended in December - Earnings Summary
Greenwich Lifesciences Inc reported a quarterly adjusted loss of 21 cents per share for the quarter ended in December. The company's reported revenue was zero; analysts expected zero. Shares of the company have fallen by 27.7% this quarter and gained 37.1% so far this year.
Reuters · 04/17 10:19
GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023
Greenwich LifeSciences reported earnings per share of -21 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -20 cents. Greenwich Lifesciences just reported results.
Investorplace · 04/16 02:53
Financial Report Articles: Comprehensive Analysis and Insights
Press release · 04/15 23:47
Weekly Report: what happened at GLSI last week (0408-0412)?
Weekly Report · 04/15 09:59
Greenwich Lifesciences Inc <GLSI.OQ> expected to post a loss of 20 cents a share - Earnings Preview
Greenwich Lifesciences Inc expected to post a loss of 20 cents a share. The one available analyst rating on the shares is "buy" The company is expected to report its quarterly results on April 16. The average analyst estimate is for the company to lose 20 cents per share.
Reuters · 04/12 20:10
Weekly Report: what happened at GLSI last week (0401-0405)?
Weekly Report · 04/08 10:02
Weekly Report: what happened at GLSI last week (0325-0329)?
Weekly Report · 04/01 10:01
Weekly Report: what happened at GLSI last week (0318-0322)?
Weekly Report · 03/25 10:03
Weekly Report: what happened at GLSI last week (0311-0315)?
Weekly Report · 03/18 10:02
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
Greenwich LifeSciences, Inc. Announces initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The company is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01. GLSI-100 is an immunotherapy to prevent breast cancer recurrences.
Barchart · 03/12 05:00
Weekly Report: what happened at GLSI last week (0304-0308)?
Weekly Report · 03/11 10:00
Weekly Report: what happened at GLSI last week (0226-0301)?
Weekly Report · 03/04 10:02
Greenwich LifeSciences Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Dow Jones · 02/28 18:33
HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $36 Price Target
Benzinga · 02/28 18:23
Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-European
TipRanks · 02/28 11:27
Greenwich LifeSciences stock jumps 8% on Phase 3 study expansion
Greenwich LifeSciences stock jumps 8% on Phase 3 study expansion. The biotech company said it has received approval to expand a breast cancer immunotherapy study into several European countries. Greenwich is testing GLSI-100 for the prevention of breast cancer recurrence.
Seeking Alpha · 02/27 15:00
Greenwich LifeSciences Flamingo-01 Phase 3 Trial Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Approved to Expand Into Five Largest European Countries
Benzinga · 02/27 11:09
More
Webull provides a variety of real-time GLSI stock news. You can receive the latest news about Greenwich Lifesciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.